홈
마켓
차트 & 아이디어
Algo
뉴스
스토어
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
히트맵
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
VKTX
#1530
Viking Therapeutics, Inc. - Common Stock
32.1
9
USD
0.00%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
0.00%
월간 변동
+5.61%
6달 변화
-10.93%
년간 변동율
+16.13%
이전 종가
32.1
9
Open
32.2
2
저가
32.0
4
High
32.5
5
양
224
마켓
US Stock Market
헬스케어
VKTX
전체 차트 열기
Full chart
Financials
개요
성명
통계
4분기
연간
Market Capitalization
3.74 B
Employee
59
Founded
2012
CEO
Brian Lian
Website
www.vikingtherapeutics.com
Headquarter
Delaware, United States
FIGI
BBG006LGV869
Industry
생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
뉴스
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
This Hot Weight-Loss Drug Stock May Have a Surprise Challenger
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Dozens of Experts Built This Simple Stock Screener for Traders & Investors. It Was Me.